Sponsored message
Logged in as
Audience-funded nonprofit news
radio tower icon laist logo
Next Up:
0:00
0:00
Subscribe
  • Listen Now Playing Listen
Health

The FDA Postpones A Highly Anticipated Meeting On The Pfizer Vaccine For Young Kids

A close-up of a hands with gloves on drawing liquid out of a vaccine vial.
A medical worker prepares the Pfizer-BioNTech COVID-19 vaccine booster in Hartford, Connecticut, in January.
(
Joseph Prezioso
/
AFP via Getty Images
)

One year ago, Congress defunded public media. Now that we're 100% community funded, please become a sustaining member or increase your existing membership today.

A highly anticipated meeting of expert advisers to discuss whether to recommend the use of the Pfizer-BioNTech COVID-19 vaccine for young children has been postponed.

The Food and Drug Administration said Pfizer told the agency that new data have recently emerged regarding its emergency use authorization request for the Pfizer vaccine in children 6 months through 4 years of age.

The agency said its preliminary assessment and need to allow more time to evaluate additional data led it to postpone the meeting scheduled for Tuesday, Feb. 15.

"We believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization," FDA officials said in a statement.

In young kids, three shots appear necessary to achieve the full immunization. The third shot, given eight weeks after the second, isn't a booster. The companies said in December that two shots for children older than age 2 but under 5 didn't prompt the expected protection.

The vaccine dose under regulatory review is 3 micrograms per shot, a tenth of the amount given to adults and teenagers. For children ages 5-11, the dose is 10 micrograms.

The application covering only the first part of the immunization series is an unorthodox regulatory move that could get vaccination moving faster. Pfizer and BioNTech said in a Feb. 1 statement that they applied for authorization this way because of the "urgent public health need."

Sponsored message

They said in the statement that they expected to submit clinical data on the third dose to FDA "in the coming months."

Copyright 2021 NPR. To see more, visit npr.org.

One year ago, Congress voted to defund public media, eliminating a critical $1.7 million from our budget every year going forward. But they couldn’t silence us, and we’re not going anywhere. LAist is now 100% community funded and that means we’re taking our future into our own hands and turning to you to keep local reporting strong.

You come to LAist because you want independent reporting and trustworthy local information. Our nonprofit newsroom doesn’t answer to shareholders looking to turn a profit. Instead, we answer to you and our communities. We are free to follow facts wherever they lead and to hold power to account without fear or favor. Our only loyalty is to our readers and listeners and our mission: to inform, engage, and strengthen Southern California’s communities.

If this story helped you, please become a monthly member today to help sustain this mission. It just takes 1 minute to donate below.
Senior Vice President News, Editor in Chief

Make your tax-deductible donation today